|Articles|September 1, 2000

HEDIS 2000: Strategies for Successful Menopause Management
Volume 6
Issue 14 Suppl

Consequences of Estrogen Deprivation and the Rationale for Hormone Replacement Therapy

Author(s)Charles B. Hammond, MD, Charles E. Rackley, MD, James Fiorica, MD

Download PDF: Consequences of Estrogen Deprivation and the Rationale for Hormone Replacement Therapy

Articles in this issue

almost 26 years ago

Article

Participating Faculty

almost 26 years ago

Article

Introduction

almost 26 years ago

Article

HEDIS Measure for the Management of Menopause

almost 26 years ago

Article

Recommendations and Plans of Action for Meeting the HEDIS 2000 Management of Menopause Measure: Overview

almost 26 years ago

Article

Medical Affairs / Provider Relations Team Recommendations

almost 26 years ago

Article

Quality Management Team Recommendations

almost 26 years ago

Article

Pharmacy Team Recommendations

almost 26 years ago

Article

Marketing / Member Relations Team Recommendations

almost 26 years ago

Article

Patient Education Team Recommendations

almost 26 years ago

Article

Appendix I: Sample of Pre-Meeting Survey Sent to Participants

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Consequences of Estrogen Deprivation and the Rationale for Hormone Replacement Therapy

Articles in this issue

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Trending on AJMC

Medicaid MFN Pricing Could Save $8.6 Billion

CRC Treatment Delays Linked to Higher Metastasis Risk, Supporting Pathway-Specific Benchmarks

Active US Drug Shortages Rise for Third Straight Quarter

Early-Onset CKD Mortality Declines Globally as Incidence Continues to Rise

Access Barriers, Not Science, Slow Retina Care: Paul Hahn, MD